These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23291985)

  • 1. Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
    Nishikawa T; Takaoka M; Ohara T; Tomono Y; Hao H; Bao X; Fukazawa T; Wang Z; Sakurama K; Fujiwara Y; Motoki T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
    Cancer Biol Ther; 2013 Mar; 14(3):230-6. PubMed ID: 23291985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
    Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
    Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
    Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
    Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
    Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
    J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.
    Gen Y; Yasui K; Nishikawa T; Yoshikawa T
    Cancer Sci; 2013 Jul; 104(7):810-6. PubMed ID: 23510069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.
    Hou G; Yang S; Zhou Y; Wang C; Zhao W; Lu Z
    J Immunol Res; 2014; 2014():845763. PubMed ID: 24818169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
    Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
    Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
    Chen Z; Yang H; Li Z; Xia Q; Nie Y
    Biochem Biophys Res Commun; 2019 Aug; 516(3):726-732. PubMed ID: 31253398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.
    Ji YM; Zhou XF; Zhang J; Zheng X; Li SB; Wei ZQ; Liu T; Cheng DL; Liu P; Song K; Tan T; Zhu H; Guo JL
    Oncotarget; 2016 Mar; 7(12):14188-98. PubMed ID: 26893358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
    Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
    Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
    Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma.
    Hirashima K; Baba Y; Watanabe M; Karashima R; Sato N; Imamura Y; Hiyoshi Y; Nagai Y; Hayashi N; Iyama K; Baba H
    Ann Surg Oncol; 2010 Sep; 17(9):2486-93. PubMed ID: 20339946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.